Market Closed -
Toronto S.E.
03:23:36 2024-05-23 pm EDT
|
5-day change
|
1st Jan Change
|
1.47
CAD
|
-5.16%
|
|
-9.82%
|
-56.12%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
559.4
|
496.7
|
153.9
|
71.99
|
26.61
|
23.97
|
-
|
-
|
Enterprise Value (EV)
1 |
559.4
|
496.7
|
153.9
|
71.99
|
26.61
|
23.97
|
23.97
|
23.97
|
P/E ratio
|
-10.3
x
|
-6.65
x
|
-1.88
x
|
-1.27
x
|
-0.33
x
|
-0.34
x
|
-0.5
x
|
-0.62
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-15.2
x
|
-7.12
x
|
-1.87
x
|
-1.24
x
|
-0.38
x
|
-0.29
x
|
-
|
-
|
EV / FCF
|
-18,745,938
x
|
-11,649,043
x
|
-2,806,630
x
|
-1,618,455
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
3.33
x
|
1.71
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
5,074
|
5,924
|
5,932
|
6,153
|
7,942
|
16,309
|
-
|
-
|
Reference price
2 |
110.2
|
83.85
|
25.95
|
11.70
|
3.350
|
1.470
|
1.470
|
1.470
|
Announcement Date
|
3/10/20
|
3/23/21
|
3/22/22
|
3/23/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-36.79
|
-69.81
|
-82.3
|
-58.03
|
-70.93
|
-83.74
|
-
|
-
|
EBIT
1 |
-37
|
-70
|
-82.49
|
-58.19
|
-71.05
|
-73.15
|
-54.41
|
-33.57
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-36.2
|
-69.34
|
-82.37
|
-57.13
|
-69.49
|
-72.52
|
-54.56
|
-32.92
|
Net income
1 |
-36.2
|
-69.34
|
-82.37
|
-57.13
|
-69.49
|
-72.52
|
-54.56
|
-32.92
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-10.75
|
-12.62
|
-13.80
|
-9.220
|
-10.29
|
-4.364
|
-2.936
|
-2.381
|
Free Cash Flow
|
-29.84
|
-42.64
|
-54.85
|
-44.48
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/23/21
|
3/22/22
|
3/23/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-30.63
|
-14.89
|
-13.68
|
-13.65
|
-14.17
|
-18.79
|
-19.34
|
-16.05
|
-16.43
|
-
|
-20.36
|
-21.44
|
-25.11
|
-
|
-
|
EBIT
1 |
-30.69
|
-14.94
|
-13.72
|
-13.69
|
-14.21
|
-18.83
|
-19.37
|
-16.08
|
-16.46
|
-13.32
|
-21.49
|
-21.79
|
-22.09
|
-14.94
|
-15.95
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-30.66
|
-14.91
|
-13.58
|
-13.35
|
-13.66
|
-18.27
|
-18.93
|
-15.75
|
-16.22
|
-13.16
|
-21.32
|
-21.62
|
-21.93
|
-15.07
|
-16.16
|
Net income
1 |
-30.66
|
-14.91
|
-13.58
|
-13.35
|
-13.66
|
-18.27
|
-18.93
|
-15.75
|
-16.22
|
-13.16
|
-21.32
|
-21.62
|
-21.93
|
-15.07
|
-16.16
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-5.104
|
-2.338
|
-2.121
|
-2.253
|
-2.254
|
-3.005
|
-3.042
|
-2.422
|
-1.954
|
-0.9964
|
-1.106
|
-1.075
|
-1.160
|
-0.9370
|
-0.9910
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/22/22
|
5/9/22
|
8/2/22
|
11/1/22
|
3/23/23
|
5/8/23
|
8/10/23
|
11/9/23
|
3/26/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-29.8
|
-42.6
|
-54.8
|
-44.5
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
25.20
|
15.20
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.14
|
0.1
|
0.27
|
0.03
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/23/21
|
3/22/22
|
3/23/23
|
3/26/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -56.12% | 17.5M | | +64.92% | 62.86B | | -1.85% | 41.38B | | +44.76% | 40.38B | | -8.93% | 27.64B | | +13.05% | 26.46B | | -21.96% | 18.9B | | +4.21% | 12.67B | | +25.74% | 12.27B | | +27.42% | 12.07B |
Other Biotechnology & Medical Research
|